Literature DB >> 20233053

Multiple myeloma may include microvessel endothelial cells of malignant origin.

Linda M Pilarski1, Patrick M Pilarski, Andrew R Belch.   

Abstract

Multiple myeloma (MM) comprises B and plasma cell compartments that originate from the same parent B cell and share as a cancer signature the same clonotypic IgH VDJ gene rearrangement. Here, we hypothesize that functional interactions between MM plasma cells (MM-PC) and their sister population of MM monocytoid B cells lead to the generation of microvessel endothelium of malignant origin from the monocytoid B cell progenitors. Published reports confirm that endothelial cells can harbor a molecular cancer signature characteristic of a given malignancy. We predict that MM monocytoid B cells-in response to both paracrine and autocrine pathways-contribute to tumor neovascularization in the bone marrow of MM patients. Our hypothesis further predicts that in MM, endothelial cells of malignant origin coexist with those of normal origin. We speculate that malignant development of MM incorporates functionally distinct sister lineages arising from the same MM progenitor that-by working together-ensure survival of the MM clone. We hypothesize that these two arms of the malignant MM clone are functionally interlinked to promote growth of the MM-PC compartment; by providing its own microenvironment, MM clonal evolution may ensure neovascularization to support an expanding malignancy.

Entities:  

Mesh:

Year:  2010        PMID: 20233053     DOI: 10.3109/10428191003661860

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

1.  NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27.

Authors:  Alessandra Dondero; Beatrice Casu; Francesca Bellora; Angelo Vacca; Annunziata De Luisi; Maria Antonia Frassanito; Claudia Cantoni; Silvia Gaggero; Daniel Olive; Alessandro Moretta; Cristina Bottino; Roberta Castriconi
Journal:  Oncotarget       Date:  2017-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.